LT2914254T - Kombinacinės terapijos chemoresistencinių vėžių gydymui - Google Patents

Kombinacinės terapijos chemoresistencinių vėžių gydymui

Info

Publication number
LT2914254T
LT2914254T LTEP13851971.5T LT13851971T LT2914254T LT 2914254 T LT2914254 T LT 2914254T LT 13851971 T LT13851971 T LT 13851971T LT 2914254 T LT2914254 T LT 2914254T
Authority
LT
Lithuania
Prior art keywords
chemoresistent
cancer
treatment
combination therapies
therapies
Prior art date
Application number
LTEP13851971.5T
Other languages
English (en)
Lithuanian (lt)
Inventor
Daniel Gold
Guillermo Garcia-Manero
Original Assignee
Mei Pharma, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mei Pharma, Inc. filed Critical Mei Pharma, Inc.
Publication of LT2914254T publication Critical patent/LT2914254T/lt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41841,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A61K31/245Amino benzoic acid types, e.g. procaine, novocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A61K31/708Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
LTEP13851971.5T 2012-10-30 2013-10-30 Kombinacinės terapijos chemoresistencinių vėžių gydymui LT2914254T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261720346P 2012-10-30 2012-10-30
PCT/US2013/067607 WO2014070948A1 (en) 2012-10-30 2013-10-30 Combination therapies

Publications (1)

Publication Number Publication Date
LT2914254T true LT2914254T (lt) 2020-04-27

Family

ID=50628036

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP13851971.5T LT2914254T (lt) 2012-10-30 2013-10-30 Kombinacinės terapijos chemoresistencinių vėžių gydymui

Country Status (16)

Country Link
US (2) US20150258068A1 (enExample)
EP (2) EP3662911A1 (enExample)
JP (1) JP6343285B2 (enExample)
CA (1) CA2927565C (enExample)
CY (1) CY1123043T1 (enExample)
DK (1) DK2914254T3 (enExample)
ES (1) ES2774296T3 (enExample)
HR (1) HRP20200521T1 (enExample)
HU (1) HUE048584T2 (enExample)
LT (1) LT2914254T (enExample)
PL (1) PL2914254T3 (enExample)
PT (1) PT2914254T (enExample)
RS (1) RS60122B1 (enExample)
SI (1) SI2914254T1 (enExample)
SM (1) SMT202000168T1 (enExample)
WO (1) WO2014070948A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI349664B (en) 2003-09-22 2011-10-01 S Bio Pte Ltd Benzimidazole derivatives: preparation and pharmaceutical applications
GB0811643D0 (en) 2008-06-25 2008-07-30 Cancer Rec Tech Ltd New therapeutic agents
WO2012048113A2 (en) 2010-10-07 2012-04-12 The General Hospital Corporation Biomarkers of cancer
US10301624B2 (en) 2014-06-25 2019-05-28 The General Hospital Corporation Targeting human satellite II (HSATII)
GB201517217D0 (en) 2015-09-29 2015-11-11 Astex Therapeutics Ltd And Cancer Res Technology Ltd Pharmaceutical compounds
GB201517216D0 (en) 2015-09-29 2015-11-11 Cancer Res Technology Ltd And Astex Therapeutics Ltd Pharmaceutical compounds
AR108257A1 (es) * 2016-05-02 2018-08-01 Mei Pharma Inc Formas polimórficas de 3-[2-butil-1-(2-dietilamino-etil)-1h-bencimidazol-5-il]-n-hidroxi-acrilamida y usos de las mismas
GB201704966D0 (en) 2017-03-28 2017-05-10 Astex Therapeutics Ltd Pharmaceutical compounds
GB201704965D0 (en) 2017-03-28 2017-05-10 Astex Therapeutics Ltd Pharmaceutical compounds
EP3749330A4 (en) 2018-02-06 2021-11-17 The General Hospital Corporation REPEATED PATTERN RNA USED AS BIOMARKERS OF TUMOR IMMUNE RESPONSE
SG11202105506UA (en) * 2018-11-30 2021-06-29 Mei Pharma Inc Combination therapies for high and very high risk mds

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
US20100098691A1 (en) * 2001-01-24 2010-04-22 S'bio Pte Ltd Combination of benzimidazole anti-cancer agent and a second anti-cancer agent
WO2003012085A1 (en) * 2001-07-30 2003-02-13 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Antigen presenting cells, method for their preparation and their use for cancer vaccines
AU2003215112A1 (en) 2002-02-07 2003-09-02 Axys Pharmaceuticals Novel bicyclic hydroxamates as inhibitors of histone deacetylase
US20040038304A1 (en) 2002-03-28 2004-02-26 Gala Design, Inc. Antibody libraries
WO2007030080A1 (en) * 2005-09-08 2007-03-15 S*Bio Pte Ltd Heterocyclic compounds
US7700567B2 (en) * 2005-09-29 2010-04-20 Supergen, Inc. Oligonucleotide analogues incorporating 5-aza-cytosine therein
CN102369204A (zh) * 2008-09-26 2012-03-07 新加坡科技研究局 3-脱氮瓶菌素衍生物

Also Published As

Publication number Publication date
CY1123043T1 (el) 2021-10-29
EP2914254A4 (en) 2016-06-29
SI2914254T1 (sl) 2020-07-31
CA2927565A1 (en) 2014-05-08
CA2927565C (en) 2021-05-18
US20150258068A1 (en) 2015-09-17
HRP20200521T1 (hr) 2020-08-07
SMT202000168T1 (it) 2020-05-08
US20210100775A1 (en) 2021-04-08
ES2774296T3 (es) 2020-07-20
EP3662911A1 (en) 2020-06-10
JP6343285B2 (ja) 2018-06-13
WO2014070948A1 (en) 2014-05-08
DK2914254T3 (en) 2020-03-30
EP2914254B1 (en) 2020-01-08
RS60122B1 (sr) 2020-05-29
JP2016501838A (ja) 2016-01-21
HUE048584T2 (hu) 2020-08-28
EP2914254A1 (en) 2015-09-09
PT2914254T (pt) 2020-04-02
PL2914254T3 (pl) 2020-09-07

Similar Documents

Publication Publication Date Title
IL289300A (en) Combination therapy for treating cancer
IL282953A (en) Agents for treatment of claudin expressing cancer diseases
HUE057061T2 (hu) Kombinációs terápia rák kezelésére
IL244014A0 (en) Combined therapy for the treatment of glioblastoma
HUE047198T2 (hu) Fitokannabinoidok emlõrák kezelésére
HUE045314T2 (hu) Kombinációs terápia rák kezelésére
HUE046667T2 (hu) Rák kombinatív kezelése
LT2914254T (lt) Kombinacinės terapijos chemoresistencinių vėžių gydymui
IL263781A (en) Combined treatment of ovarian cancer
EP2830633A4 (en) COMBINATION THERAPY FOR CANCER TREATMENT
PL3511004T3 (pl) Preparaty skojarzone do leczenia raka
PL3062790T3 (pl) Połączenia farmaceutyczne do leczenia raka
IL242546A0 (en) New compounds for cancer treatment
IL245551A0 (en) Anti-matriptase antibodies for cancer treatment
HUE047920T2 (hu) GD2-pozitív rák kezelésére szolgáló készítmények
HUE049301T2 (hu) Kurkofenol-vegyület rák kezelésére
PL2855475T3 (pl) Alfa-karboliny do leczenia nowotworu
PL3016948T3 (pl) 2-acyloaminotiazole do leczenia nowotworów
IL233495A0 (en) Combination for cancer treatment
AP2015008905A0 (en) Novel compounds for the treatment of cancer
GB201322346D0 (en) Combination treatment of cancer